Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ in oncology and inflammation.

Biotechnology

Immix Biopharma

Immix Biopharma's headquarters in Los Angeles, CA, United States

Ilya Rachman

Graham Ross

Eva Altow

Gabriel Morris

Carey Ng

Jane Buchan

Gary Schiller

Magda Marquet

Sean Senn

Larry Norton

Sant Chawla

Razelle Kurzrock

Galit Lahav

George W. Sledge

Vladimir Torchilin

Jason Hsu

Helen C. Adams

The Board of Directors at Immix Biopharma oversees corporate governance, strategic direction, and financial stewardship to ensure the company's advancements in Tissue-Specific Therapeutics (TSTx)™ align with its goals in oncology and inflammation. They provide executive oversight, monitor performance, and make pivotal decisions to guide the clinical-stage biopharmaceutical company toward sustainable growth and innovation.

Board of Directors

The Scientific Advisory Team at Immix Biopharma provides strategic guidance and expert insights on the development of Tissue-Specific Therapeutics (TSTx)™. They advise on clinical trials, research methodologies, and scientific innovations in oncology and inflammation to support the company's mission and ensure the potential for therapeutic breakthroughs.

Scientific Advisory Team

The Leadership Team at Immix Biopharma is responsible for guiding the strategic vision and operational direction of the company. This diverse group, comprising co-founders and top executives, collaborates to advance the development of innovative Tissue-Specific Therapeutics (TSTx)™ in the fields of oncology and inflammation, ensuring alignment with clinical goals, financial health, and overall organizational growth. Their collective expertise drives decision-making and fosters a culture of innovation in a rapidly evolving biopharmaceutical landscape.

Leadership Team

The Clinical Development Team at Immix Biopharma is responsible for designing, planning, and overseeing clinical trials to evaluate the safety and efficacy of Tissue-Specific Therapeutics (TSTx)™. This includes developing clinical protocols, managing trial logistics, ensuring regulatory compliance, and coordinating between various stakeholders to advance oncology and inflammation therapies through the clinical pipeline.

Immix Biopharma

Org chart

Board & advisors

Teams

Board of Directors

Scientific Advisory Team

Leadership Team

Clinical Development Team

Offices

Immix Biopharma

Org chart

Board & advisors

Teams

Board of Directors

Scientific Advisory Team

Leadership Team

Clinical Development Team

Offices

Related companies